Influenza Diagnostics Market by Type (Traditional (Rapid Influenza Detection Tests, Viral Culture, Immunoassay Kits, Others), Molecular (Rapid Molecular Assays, Reverse Transcription-Polymerase Chain Reaction {RT-PCR}, Nucleic Acid Amplification)), End-User (Clinical Laboratories, Hospitals, Research & Academic Institutes, Diagnostic Laboratories) and by Region Global Trends and Forecast from 2022 to 2029

Published on: Oct 2023
From:USD $3499.00
Number Of Pages:59

Please Choose License Type

Single User

Team User

Corporate License

Request a Sample

INTERESTED IN THIS RESEARCH?

Contact our analysts for inquiries, samples, and expert insights.

Market Size	CAGR	Dominating Region
USD 1.01 billion in 2020	8.3 %	North America

by Product	by Technology	by Regions
Traditional Rapid Influenza Detection Tests Viral Culture Immunoassay Kits Others Molecular Rapid Molecular Assays Reverse Transcription-Polymerase Chain Reaction {RT-PCR} Nucleic Acid Amplification	Clinical Laboratories Hospitals Research & Academic Institutes Diagnostic Laboratories	North America Europe Asia Pacific South America Middle East and Africa

4.3/5 - (15 votes)

Influenza Diagnostics Market Overview

The global influenza diagnostics market is projected to reach USD 1.92 billion by 2029 from USD 1.01 billion in 2020, at a CAGR of 8.3 % from 2022 to 2029.

The influenza A or influenza B viruses are thought to be the primary cause of this extremely contagious respiratory illness. People who have the flu can infect others by transmitting the virus through their respiratory secretions. The most prevalent method of illness transmission is by coughing and sneezing. Children, adults, and newborns all have a significant burden of sickness from influenza. In point of care (POC) investigations, there is currently a dearth of biomarkers for monitoring influenza illness. Fluorescence-based fast diagnostic methods have recently been used to increase the sensitivity of the first diagnosis. Due to a variety of nonspecific causes, diagnosing influenza based only on clinical indications is challenging. Potential advantages from a precise and speedy diagnosis of influenza infection are also provided by the findings of the diagnostic tests.

The accurate and timely diagnosis of influenza is crucial for several reasons. First, it helps to guide appropriate treatment with antiviral medications, which can reduce the duration and severity of illness. Second, it allows for the implementation of infection prevention and control measures to prevent further transmission of the virus to others. Third, it is essential for surveillance and monitoring of influenza activity in the population, which is critical for public health planning and response.

Influenza Diagnostics Market | Exactitude Consultancy

Growth in the influenza diagnostics market revenue is attributed to a number of variables, including an increase in influenza cases, technical developments, the use of fast diagnostic tests more often, and an increase in R&D efforts. The rising worldwide burden of infectious diseases has led to a rise in the demand for diagnostic tools for influenza and other illnesses. Influenza is becoming more prevalent globally, which has accelerated R&D work on effective diagnosis and detection.

The goal of research is to improve influenza diagnostics, with the expectation that doing so will result in increased market income. The global use of these diagnostic tests will rise as a result of increased research and development spending since it will bring more cutting-edge methods for detecting influenza. Due to a rise in influenza prevalence and widespread use of these tests, rapid influenza diagnostic testing is predicted to produce considerable revenue in the upcoming years. Numerous initiatives and research funds are also contributing to the market’s expansion.

The price of diagnostic testing is a major barrier. Some tests, like NAATs, might be expensive, which restricts their accessibility and application to some groups. Additionally, some healthcare systems do not pay for some diagnostic tests, which prevents many patients from accessing them. The variability in diagnostic test accuracy is another important constraint. Rapid diagnostic tests, while fast and easy to perform, have lower sensitivity than more accurate tests such as NAATs and viral culture. False-negative results can occur, particularly in the early stages of infection when the viral load is low. This variability can lead to delayed or missed diagnoses, potentially resulting in further transmission of the virus.

The creation of diagnostic tests that are more precise and dependable is a big opportunity. While current tests provide useful information, there is room for improvement in terms of accuracy and sensitivity. The development of new diagnostic technologies that can provide results quickly and accurately could lead to better patient outcomes and more effective management of influenza outbreaks. here is an opportunity to integrate diagnostic testing with other technologies, such as telemedicine and electronic health records. This integration could lead to more efficient and streamlined healthcare delivery, particularly in rural or remote areas where access to healthcare is limited.

ATTRIBUTE	DETAILS
Study period	2022-2029
Base year	2022
Estimated year	2023
Forecasted year	2023-2029
Historical period	2018-2022
Unit	Value (USD Billion)
Segmentation	By Product, By Technology, By Application, By Region
By Type	Traditional Rapid Influenza Detection Tests Viral Culture Immunoassay Kits Others Molecular Rapid Molecular Assays Reverse Transcription-Polymerase Chain Reaction {RT-PCR} Nucleic Acid Amplification
By End-User	Clinical Laboratories Hospitals Research & Academic Institutes Diagnostic Laboratories
By Region	North America Europe Asia Pacific South America MEA

Influenza Diagnostics Market Segment Analysis

The global influenza diagnostics market is segmented by type, end-user, and region.

Based on type, the influenza diagnostics market is classified into Traditional (Rapid Influenza Detection Tests, Viral Culture, Immunoassay Kits, Others), Molecular (Rapid Molecular Assays, Reverse Transcription-Polymerase Chain Reaction {RT-PCR}, Nucleic Acid Amplification). The traditional test category known as Rapid Influenza Detection Tests (RIDTs), is anticipated to rule the influenza diagnostic market. The key element boosting the development of this market is the capacity to identify influenza viruses within 15 minutes with low to moderate sensitivity and high specificity. Additionally, an analyzer reading device can be used to standardize the findings of RIDTs and increase their sensitivity. The Clinical Laboratory Improvement Amendment (CLIA) has been waived for many RIDTs, making them relatively easy to execute and without requiring the expertise of scientists.

The molecular test segment’s RT-PCR test is anticipated to see the greatest growth rate over the projection period. The healthcare professional can tell who is now infected and who is not by using an RT-PCR test to identify current influenza infection. Additionally, it is a very sensitive test that can also identify the presence of influenza virus in low concentrations, which is what is driving the RT PCR test’s rapid development throughout the projected period.

Based on end-user, the influenza diagnostics market is bifurcated into clinical laboratories, hospitals, research & academic institutes, diagnostic laboratories. The hospital sector accounted for the biggest revenue share in 2021. The yearly emergence of the influenza virus is accompanied by a high rate of hospital admissions. The quantity of hospitalizations reflects the possible severity of the condition. Prior to becoming ill with influenza, it’s crucial to address any underlying diseases since the virus can exacerbate existing problems and make hospitalization necessary. At the beginning of flu season, the fast spread of influenza and other respiratory viruses is alarming medical professionals and taxing hospitals.

In terms of revenue, the diagnostic centres market segment had a sizable market share for influenza diagnostics globally in 2022. This is brought about by the expansion of diagnostic centre networks, which are housed in sophisticated buildings and have access to a broad variety of influenza diagnostic testing kits.

Influenza Diagnostics Market Players

The global influenza diagnostics market key players include Roche Diagnostics, Quidel Corporation, Thermo Fisher Scientific Inc., Abbott Laboratories, Hologic, Inc., Becton, Dickinson and Company, Danaher Corporation, DiaSorin S.p.A., Meridian Bioscience, Inc., Sekisui Diagnostics LLC, Luminex Corporation, F. Hoffmann-La Roche AG, SA Scientific Ltd.

Industry Developments:

March 17, 2023: DiaSorin (FTSE MIB: DIA) announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Simplexa™ COVID-19 & Flu A/B Direct assay.

Feb. 8, 2023: BD announced that it has received Emergency Use Authorization from the U.S. Food and Drug Administration (FDA) for a new molecular diagnostic combination test for SARS-CoV-2, Influenza A + B and Respiratory Syncytial Virus (RSV) to aid combat illness in the current and future respiratory virus seasons.

Who Should Buy? Or Key stakeholders

Healthcare providers
Medical laboratory professionals
Medical device manufacturers
Government and public health organizations
Research institutions and academic organizations
Regulatory authorities
End-Users

Influenza Diagnostics Market Regional Analysis

The influenza diagnostics market by region includes North America, Asia-Pacific (APAC), Europe, South America, and Middle East & Africa (MEA).

North America: includes the US, Canada, Mexico
Asia Pacific: includes China, Japan, South Korea, India, Australia, ASEAN and Rest of APAC
Europe: includes UK, Germany, France, Italy, Spain, Russia, and Rest of Europe
South America: includes Brazil, Argentina and Rest of South America
Middle East & Africa: includes Turkey, UAE, Saudi Arabia, South Africa, and Rest of MEA

North America had a sizable market share for influenza diagnostics in 2021. It is likely to maintain its dominance during the forecast period. Due to the expansion of the healthcare industry and the quick uptake of influenza diagnostic tools, it is projected that the market in the area would rise in the near future. Increased use of new technologies is also anticipated to favorably affect the future for the North American influenza diagnostics market. The U.S. dominated the North American market for influenza diagnostic testing. Due to the increasing prevalence of influenza and hospitalization in the United States, the sector is anticipated to have significant growth throughout the forecasted period. The US has a high national market share due to the vast patient population.

The influenza diagnostics market’s revenue share from the Asia Pacific region was second-largest in 2021. The desire for enhanced wellness care services and the growing senior population, as well as improved infrastructure, more accessible healthcare, and favorable reimbursement conditions for medical tests, are all contributing factors. Additionally, a recent cost-effectiveness analysis shows that vaccination against the flu for elderly people financed by the government is economical for influenza control and prevention in China.

Key Market Segments: Influenza Diagnostics Market

Influenza Diagnostics Market by Product 2022-2029, (USD Billion)

Traditional
- Rapid Influenza Detection Tests
- Viral Culture
- Immunoassay Kits
- Others
Molecular
- Rapid Molecular Assays
- Reverse Transcription-Polymerase Chain Reaction {RT-PCR}
- Nucleic Acid Amplification

Influenza Diagnostics Market by Technology, 2022-2029, (USD Billion)

Clinical Laboratories
Hospitals
Research & Academic Institutes
Diagnostic Laboratories

Influenza Diagnostics Market by Regions, 2022-2029, (USD Billion)

North America
Europe
Asia Pacific
South America
Middle East and Africa

Important Countries in All Regions Are Covered

Exactitude Consultancy Services Key Objectives:

Increasing sales and market share
Developing new technology
Improving profitability
Entering new markets
Enhancing brand reputation

Key Question Answered

What is the expected growth rate of the influenza diagnostics market over the next 7 years?
Who are the major players in the influenza diagnostics market and what is their market share?
What are the end-user industries driving demand for market and what is their outlook?
What are the opportunities for growth in emerging markets such as Asia-Pacific, Middle East, and Africa?
How is the economic environment affecting the influenza diagnostics market, including factors such as interest rates, inflation, and exchange rates?
What is the expected impact of government policies and regulations on the influenza diagnostics market?
What is the current and forecasted size and growth rate of the global influenza diagnostics market?
What are the key drivers of growth in the influenza diagnostics market?
What are the distribution channels and supply chain dynamics in the influenza diagnostics market?
What are the technological advancements and innovations in the influenza diagnostics market and their impact on product development and growth?
What are the regulatory considerations and their impact on the market?
What are the challenges faced by players in the influenza diagnostics market and how are they addressing these challenges?
What are the opportunities for growth and expansion in the influenza diagnostics market?
What are the service offerings and specifications of leading players in the market?

INTRODUCTION
1. MARKET DEFINITION
2. MARKET SEGMENTATION
3. RESEARCH TIMELINES
4. ASSUMPTIONS AND LIMITATIONS
RESEARCH METHODOLOGY
1. DATA MINING
  1. SECONDARY RESEARCH
  2. PRIMARY RESEARCH
  3. SUBJECT-MATTER EXPERTS’ ADVICE
2. QUALITY CHECKS
  1. FINAL REVIEW
3. DATA TRIANGULATION
  1. BOTTOM-UP APPROACH
  2. TOP-DOWN APPROACH
  3. RESEARCH FLOW
4. DATA SOURCES
EXECUTIVE SUMMARY
MARKET OVERVIEW
1. GLOBAL INFLUENZA DIAGNOSTICS MARKET OUTLOOK
  1. MARKET DRIVERS
  2. MARKET RESTRAINTS
  3. MARKET OPPORTUNITIES
2. IMPACT OF COVID-19 ON INFLUENZA DIAGNOSTICS MARKET
3. PORTER’S FIVE FORCES MODEL
  1. THREAT FROM NEW ENTRANTS
  2. THREAT FROM SUBSTITUTES
  3. BARGAINING POWER OF SUPPLIERS
  4. BARGAINING POWER OF CUSTOMERS
  5. DEGREE OF COMPETITION
4. INDUSTRY VALUE CHAIN ANALYSIS
GLOBAL INFLUENZA DIAGNOSTICS MARKET BY TYPE, 2020-2029, (USD BILLION)
1. TRADITIONAL
  1. RAPID INFLUENZA DETECTION TESTS
  2. VIRAL CULTURE
  3. IMMUNOASSAY KITS
  4. OTHERS
2. MOLECULAR
  1. RAPID MOLECULAR ASSAYS
  2. REVERSE TRANSCRIPTION-POLYMERASE CHAIN REACTION {RT-PCR}
  3. NUCLEIC ACID AMPLIFICATION

GLOBAL INFLUENZA DIAGNOSTICS MARKET BY END-USER, 2020-2029, (USD BILLION)
1. CLINICAL LABORATORIES
2. HOSPITALS
3. RESEARCH & ACADEMIC INSTITUTES
4. DIAGNOSTIC LABORATORIES
GLOBAL INFLUENZA DIAGNOSTICS MARKET BY REGION, 2020-2029, (USD BILLION)
1. NORTH AMERICA
  1. US
  2. CANADA
  3. MEXICO
2. SOUTH AMERICA
  1. BRAZIL
  2. ARGENTINA
  3. COLOMBIA
  4. REST OF SOUTH AMERICA
3. EUROPE
  1. GERMANY
  2. UK
  3. FRANCE
  4. ITALY
  5. SPAIN
  6. RUSSIA
  7. REST OF EUROPE
4. ASIA PACIFIC
  1. INDIA
  2. CHINA
  3. JAPAN
  4. SOUTH KOREA
  5. AUSTRALIA
  6. SOUTH-EAST ASIA
  7. REST OF ASIA PACIFIC
5. MIDDLE EAST AND AFRICA
  1. UAE
  2. SAUDI ARABIA
  3. SOUTH AFRICA
  4. REST OF MIDDLE EAST AND AFRICA

COMPANY PROFILES* (BUSINESS OVERVIEW, COMPANY SNAPSHOT, PRODUCT OFFERED, RECENT DEVELOPMENTS)

ROCHE DIAGNOSTICS
QUIDEL CORPORATION
THERMO FISHER SCIENTIFIC INC.
ABBOTT LABORATORIES
HOLOGIC, INC.
BP PLC
BECTON, DICKINSON AND COMPANY
DANAHER CORPORATION
DIASORIN S.P.A.
MERIDIAN BIOSCIENCE, INC.
SEKISUI DIAGNOSTICS LLC
LUMINEX CORPORATION
F. HOFFMANN-LA ROCHE AG
SA SCIENTIFIC LTD*THE COMPANY LIST IS INDICATIVE

LIST OF TABLES

TABLE 1 GLOBAL INFLUENZA DIAGNOSTICS MARKET BY TYPE (USD BILLION) 2020-2029

TABLE 2 GLOBAL INFLUENZA DIAGNOSTICS MARKET BY END-USER (USD BILLION) 2020-2029

TABLE 3 GLOBAL INFLUENZA DIAGNOSTICS MARKET BY REGION (USD BILLION) 2020-2029

TABLE 4 NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET BY COUNTRY (USD BILLION) 2020-2029

TABLE 5 NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET BY TYPE (USD BILLION) 2020-2029

TABLE 6 NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET BY END-USER (USD BILLION) 2020-2029

TABLE 7 US INFLUENZA DIAGNOSTICS MARKET BY TYPE (USD BILLION) 2020-2029

TABLE 8 US INFLUENZA DIAGNOSTICS MARKET BY END-USER (USD BILLION) 2020-2029

TABLE 9 CANADA INFLUENZA DIAGNOSTICS MARKET BY TYPE (USD BILLION) 2020-2029

TABLE 10 CANADA INFLUENZA DIAGNOSTICS MARKET BY END-USER (USD BILLION) 2020-2029

TABLE 11 MEXICO INFLUENZA DIAGNOSTICS MARKET BY TYPE (USD BILLION) 2020-2029

TABLE 12 MEXICO INFLUENZA DIAGNOSTICS MARKET BY END-USER (USD BILLION) 2020-2029

TABLE 13 SOUTH AMERICA INFLUENZA DIAGNOSTICS MARKET BY COUNTRY (USD BILLION) 2020-2029

TABLE 14 SOUTH AMERICA INFLUENZA DIAGNOSTICS MARKET BY TYPE (USD BILLION) 2020-2029

TABLE 15 SOUTH AMERICA INFLUENZA DIAGNOSTICS MARKET BY END-USER (USD BILLION) 2020-2029

TABLE 16 BRAZIL INFLUENZA DIAGNOSTICS MARKET BY TYPE (USD BILLION) 2020-2029

TABLE 17 BRAZIL INFLUENZA DIAGNOSTICS MARKET BY END-USER (USD BILLION) 2020-2029

TABLE 18 ARGENTINA INFLUENZA DIAGNOSTICS MARKET BY TYPE (USD BILLION) 2020-2029

TABLE 19 ARGENTINA INFLUENZA DIAGNOSTICS MARKET BY END-USER (USD BILLION) 2020-2029

TABLE 20 COLOMBIA INFLUENZA DIAGNOSTICS MARKET BY TYPE (USD BILLION) 2020-2029

TABLE 21 COLOMBIA INFLUENZA DIAGNOSTICS MARKET BY END-USER (USD BILLION) 2020-2029

TABLE 22 REST OF SOUTH AMERICA INFLUENZA DIAGNOSTICS MARKET BY TYPE (USD BILLION) 2020-2029

TABLE 23 REST OF SOUTH AMERICA INFLUENZA DIAGNOSTICS MARKET BY END-USER (USD BILLION) 2020-2029

TABLE 24 ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET BY COUNTRY (USD BILLION) 2020-2029

TABLE 25 ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET BY TYPE (USD BILLION) 2020-2029

TABLE 26 ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET BY END-USER (USD BILLION) 2020-2029

TABLE 27 INDIA INFLUENZA DIAGNOSTICS MARKET BY TYPE (USD BILLION) 2020-2029

TABLE 28 INDIA INFLUENZA DIAGNOSTICS MARKET BY END-USER (USD BILLION) 2020-2029

TABLE 29 CHINA INFLUENZA DIAGNOSTICS MARKET BY TYPE (USD BILLION) 2020-2029

TABLE 30 CHINA INFLUENZA DIAGNOSTICS MARKET BY END-USER (USD BILLION) 2020-2029

TABLE 31 JAPAN INFLUENZA DIAGNOSTICS MARKET BY TYPE (USD BILLION) 2020-2029

TABLE 32 JAPAN INFLUENZA DIAGNOSTICS MARKET BY END-USER (USD BILLION) 2020-2029

TABLE 33 SOUTH KOREA INFLUENZA DIAGNOSTICS MARKET BY TYPE (USD BILLION) 2020-2029

TABLE 34 SOUTH KOREA INFLUENZA DIAGNOSTICS MARKET BY END-USER (USD BILLION) 2020-2029

TABLE 35 AUSTRALIA INFLUENZA DIAGNOSTICS MARKET BY TYPE (USD BILLION) 2020-2029

TABLE 36 AUSTRALIA INFLUENZA DIAGNOSTICS MARKET BY END-USER (USD BILLION) 2020-2029

TABLE 37 SOUTH-EAST ASIA INFLUENZA DIAGNOSTICS MARKET BY TYPE (USD BILLION) 2020-2029

TABLE 38 SOUTH-EAST ASIA INFLUENZA DIAGNOSTICS MARKET BY END-USER (USD BILLION) 2020-2029

TABLE 39 REST OF ASIA PACIFIC INFLUENZA DIAGNOSTICS MARKET BY TYPE (USD BILLION) 2020-2029

TABLE 40 REST OF ASIA PACIFIC INFLUENZA DIAGNOSTICS MARKET BY END-USER (USD BILLION) 2020-2029

TABLE 41 EUROPE INFLUENZA DIAGNOSTICS MARKET BY COUNTRY (USD BILLION) 2020-2029

TABLE 42 EUROPE INFLUENZA DIAGNOSTICS MARKET BY TYPE (USD BILLION) 2020-2029

TABLE 43 EUROPE INFLUENZA DIAGNOSTICS MARKET BY END-USER (USD BILLION) 2020-2029

TABLE 44 GERMANY INFLUENZA DIAGNOSTICS MARKET BY TYPE (USD BILLION) 2020-2029

TABLE 45 GERMANY INFLUENZA DIAGNOSTICS MARKET BY END-USER (USD BILLION) 2020-2029

TABLE 46 UK INFLUENZA DIAGNOSTICS MARKET BY TYPE (USD BILLION) 2020-2029

TABLE 47 UK INFLUENZA DIAGNOSTICS MARKET BY END-USER (USD BILLION) 2020-2029

TABLE 48 FRANCE INFLUENZA DIAGNOSTICS MARKET BY TYPE (USD BILLION) 2020-2029

TABLE 49 FRANCE INFLUENZA DIAGNOSTICS MARKET BY END-USER (USD BILLION) 2020-2029

TABLE 50 ITALY INFLUENZA DIAGNOSTICS MARKET BY TYPE (USD BILLION) 2020-2029

TABLE 51 ITALY INFLUENZA DIAGNOSTICS MARKET BY END-USER (USD BILLION) 2020-2029

TABLE 52 SPAIN INFLUENZA DIAGNOSTICS MARKET BY TYPE (USD BILLION) 2020-2029

TABLE 53 SPAIN INFLUENZA DIAGNOSTICS MARKET BY END-USER (USD BILLION) 2020-2029

TABLE 54 RUSSIA INFLUENZA DIAGNOSTICS MARKET BY TYPE (USD BILLION) 2020-2029

TABLE 55 RUSSIA INFLUENZA DIAGNOSTICS MARKET BY END-USER (USD BILLION) 2020-2029

TABLE 56 REST OF EUROPE INFLUENZA DIAGNOSTICS MARKET BY TYPE (USD BILLION) 2020-2029

TABLE 57 REST OF EUROPE INFLUENZA DIAGNOSTICS MARKET BY END-USER (USD BILLION) 2020-2029

TABLE 58 MIDDLE EAST AND AFRICA INFLUENZA DIAGNOSTICS MARKET BY COUNTRY (USD BILLION) 2020-2029

TABLE 59 MIDDLE EAST AND AFRICA INFLUENZA DIAGNOSTICS MARKET BY TYPE (USD BILLION) 2020-2029

TABLE 60 MIDDLE EAST AND AFRICA INFLUENZA DIAGNOSTICS MARKET BY END-USER (USD BILLION) 2020-2029

TABLE 61 UAE INFLUENZA DIAGNOSTICS MARKET BY TYPE (USD BILLION) 2020-2029

TABLE 62 UAE INFLUENZA DIAGNOSTICS MARKET BY END-USER (USD BILLION) 2020-2029

TABLE 63 SAUDI ARABIA INFLUENZA DIAGNOSTICS MARKET BY TYPE (USD BILLION) 2020-2029

TABLE 64 SAUDI ARABIA INFLUENZA DIAGNOSTICS MARKET BY END-USER (USD BILLION) 2020-2029

TABLE 65 SOUTH AFRICA INFLUENZA DIAGNOSTICS MARKET BY TYPE (USD BILLION) 2020-2029

TABLE 66 SOUTH AFRICA INFLUENZA DIAGNOSTICS MARKET BY END-USER (USD BILLION) 2020-2029

TABLE 67 REST OF MIDDLE EAST AND AFRICA INFLUENZA DIAGNOSTICS MARKET BY TYPE (USD BILLION) 2020-2029

TABLE 68 REST OF MIDDLE EAST AND AFRICA INFLUENZA DIAGNOSTICS MARKET BY END-USER (USD BILLION) 2020-2029

LIST OF FIGURES

FIGURE 1 MARKET DYNAMICS

FIGURE 2 MARKET SEGMENTATION

FIGURE 3 REPORT TIMELINES: YEARS CONSIDERED

FIGURE 4 DATA TRIANGULATION

FIGURE 5 BOTTOM-UP APPROACH

FIGURE 6 TOP-DOWN APPROACH

FIGURE 7 RESEARCH FLOW

FIGURE 8 GLOBAL INFLUENZA DIAGNOSTICS MARKET BY TYPE (USD BILLION) 2020-2029

FIGURE 9 GLOBAL INFLUENZA DIAGNOSTICS MARKET BY END-USER (USD BILLION) 2020-2029

FIGURE 11 GLOBAL INFLUENZA DIAGNOSTICS MARKET BY REGION (USD BILLION) 2020-2029

FIGURE 12 PORTER’S FIVE FORCES MODEL

FIGURE 13 GLOBAL INFLUENZA DIAGNOSTICS MARKET BY TYPE (USD BILLION) 2021

FIGURE 14 GLOBAL INFLUENZA DIAGNOSTICS MARKET BY END-USER (USD BILLION) 2021

FIGURE 16 GLOBAL INFLUENZA DIAGNOSTICS MARKET BY REGION (USD BILLION) 2021

FIGURE 17 MARKET SHARE ANALYSIS

FIGURE 18 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT

FIGURE 19 QUIDEL CORPORATION: COMPANY SNAPSHOT

FIGURE 20 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT

FIGURE 21 ABBOTT LABORATORIES: COMPANY SNAPSHOT

FIGURE 22 HOLOGIC, INC.: COMPANY SNAPSHOT

FIGURE 23 BP PLC: COMPANY SNAPSHOT

FIGURE 24 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT

FIGURE 25 DANAHER CORPORATION: COMPANY SNAPSHOT

FIGURE 26 DIASORIN S.P.A.: COMPANY SNAPSHOT

FIGURE 27 MERIDIAN BIOSCIENCE, INC.: COMPANY SNAPSHOT

FIGURE 28 SEKISUI DIAGNOSTICS LLC: COMPANY SNAPSHOT

FIGURE 29 LUMINEX CORPORATION: COMPANY SNAPSHOT

FIGURE 30 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT

FIGURE 31 SA SCIENTIFIC LTD: COMPANY SNAPSHOT

What is the worth of the influenza diagnostics market?

The global influenza diagnostics market is projected to reach USD 1.92 billion by 2029 from USD 1.01 billion in 2020, at a CAGR of 8.3 % from 2022 to 2029.

What is the share of the North America influenza diagnostics industry?

Which are the top companies to hold the market share in the influenza diagnostics market?

What is the CAGR of influenza diagnostics market?

The global influenza diagnostics market registered a CAGR of 8.3 % from 2022 to 2029.

What are the key factors driving the market?

The increasing prevalence of influenza, emergence of technologically advanced influenza diagnostic, and growth in research funding for influenza diagnostics are the key factors driving the market.

In-Depth Database

Our Report’s database covers almost all topics of all regions over the Globe.

Recognised Publishing Sources

Tie ups with top publishers around the globe.

Customer Support

Complete pre and post sales
support.

Safe & Secure

Complete secure payment
process.

INTERESTED IN THIS RESEARCH?

REPORT OUTLOOK

SCOPE OF THE REPORT